<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fried, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Direct-Acting Antiviral Therapy Produces High SVR12 in HCV GT-1 Cirrhotic Patients Regardless of Baseline Characteristics</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of cirrhotic, hepatitis C virus (HCV) genotype 1 (GT-1)-infected patients with a twice-daily oral regimen involving a single tablet of 3 direct-acting antiviral agents - the HCV NS3/4A serine protease inhibitor ABT-450 at 150 mg plus ritonavir 100 mg plus the NS5A inhibitor ombitasvir 25 mg - along with a tablet of dasabuvir 250 mg and a tablet of ribavirin yields high rates of sustained virologic response 12 weeks following conclusion of treatment. The findings of the large, international, phase 3 TURQUOISE-II trial are discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>